Zacks Research Comments on Omnicell, Inc.’s FY2025 Earnings (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research increased their FY2025 earnings per share estimates for shares of Omnicell in a research report issued to clients and investors on Tuesday, October 1st. Zacks Research analyst U. Biswas now expects that the company will post earnings of $0.52 per share for the year, up from their previous forecast of $0.49. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share.

A number of other equities analysts have also commented on OMCL. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Benchmark reissued a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a research note on Monday, July 15th. Wells Fargo & Company boosted their target price on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Finally, Bank of America boosted their target price on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $37.83.

Omnicell Price Performance

Omnicell stock opened at $42.39 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The firm has a market cap of $1.95 billion, a P/E ratio of -92.15, a P/E/G ratio of 47.43 and a beta of 0.83. The business’s fifty day moving average is $42.08 and its two-hundred day moving average is $33.32. Omnicell has a 52 week low of $25.12 and a 52 week high of $46.05.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. Omnicell’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.29 EPS.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its holdings in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares in the last quarter. EntryPoint Capital LLC increased its holdings in shares of Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after acquiring an additional 1,345 shares in the last quarter. CWM LLC increased its holdings in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares in the last quarter. Benjamin Edwards Inc. increased its holdings in shares of Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after acquiring an additional 868 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Omnicell in the second quarter worth about $104,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.